Adderal pills, 20 mg

Prescription stimulants, such as methylphenidate (e.g., Ritalin) and amphetamine compounds (e.g., dextroamphetamine; Adderall), have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of attention deficit hyperactivity disorder (ADHD). These medications are available in short, intermediate, and long-acting (i.e., sustained release) forms.

 

Reports (2018-2024)

A new DEA-commissioned report looks at buprenorphine treatment for substance use disorder. From 2018 to 2024, the number of patients dispensed buprenorphine increased by 53% across all geographic regions. The increase in total users was largely driven by longer-term users.

IQVIA Report on Buprenorphine Treatment for Substance Use (PDF) (October 2024)

Reports (2012-2021)

In response to the growing problems of opioid overdose involving stimulants and reported increases in prescription stimulant use, DEA released two additional reports that assessed trends related to prescription stimulant use in the U.S. from 2012-2021.

IQVIA Report on Stimulant Prescription Trends from 2012–2022 (PDF) (August 2023)

IQVIA Report on Stimulant Prescription Trends from 2012–2021 (PDF) (October 2022)

General Stimulant Information

DEA Fact Sheet on Stimulants (October 2022)